ArticleCancers2020

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.

Filippo de Braud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.